Optimer Pharmaceuticals is an emerging biopharmaceutical company with a number of late stage anti-infective drugs in its pipeline. These drug candidates target the treatment of life-threatening bacterial infections. The company also specializes in using its proprietary synthetic glycol-chemistry technology for drug discovery. It was founded and registered as a Delaware Corporation in 1998. The company has licensed its technologies and therapeutic targets from The Scripps Research Institute and The Memorial Sloan-Kettering Cancer Center. These licenses form the core of Optimer's carbohydrate technologies. Optimer Pharmaceuticals is located in San Diego.